HKSE - Delayed Quote HKD

Shanghai Junshi Biosciences Co., Ltd. (1877.HK)

9.720 +0.070 (+0.73%)
As of 3:52 PM GMT+8. Market Open.
Loading Chart for 1877.HK
DELL
  • Previous Close 9.650
  • Open 9.660
  • Bid 9.720 x --
  • Ask 9.740 x --
  • Day's Range 9.510 - 9.830
  • 52 Week Range 9.170 - 31.100
  • Volume 1,270,984
  • Avg. Volume 1,240,529
  • Market Cap (intraday) 22.831B
  • Beta (5Y Monthly) 0.40
  • PE Ratio (TTM) --
  • EPS (TTM) -2.510
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 39.24

Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of oncology, metabolic, autoimmune, neurologic, nervous system, and infectious diseases in the People's Republic of China. The company was founded in 2012 and is headquartered in Shanghai, People's Republic of China.

www.junshipharma.com

2,568

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 1877.HK

Performance Overview: 1877.HK

Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

1877.HK
50.00%
HANG SENG INDEX
0.70%

1-Year Return

1877.HK
69.58%
HANG SENG INDEX
14.49%

3-Year Return

1877.HK
88.47%
HANG SENG INDEX
40.96%

5-Year Return

1877.HK
70.99%
HANG SENG INDEX
42.71%

Compare To: 1877.HK

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 1877.HK

Valuation Measures

Annual
As of 4/23/2024
  • Market Cap

    22.67B

  • Enterprise Value

    20.51B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    5.85

  • Price/Book (mrq)

    1.23

  • Enterprise Value/Revenue

    13.65

  • Enterprise Value/EBITDA

    -8.34

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -151.97%

  • Return on Assets (ttm)

    -12.95%

  • Return on Equity (ttm)

    -29.66%

  • Revenue (ttm)

    1.5B

  • Net Income Avi to Common (ttm)

    -2.28B

  • Diluted EPS (ttm)

    -2.510

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    3.79B

  • Total Debt/Equity (mrq)

    24.43%

  • Levered Free Cash Flow (ttm)

    -2.11B

Research Analysis: 1877.HK

Analyst Price Targets

17.36
39.24 Average
9.720 Current
111.27 High
 

Fair Value

 

Company Insights: 1877.HK

People Also Watch